Related Experiment Videos
Distinct requirements for IFNs and STAT1 in NK cell function
1Department of Pathology, Kaplan Comprehensive Cancer Center, New York University School of Medicine, NY 10016, USA.
Abstract:
NK cell functions were examined in mice with a targeted mutation of the STAT1 gene, an essential mediator of IFN signaling. Mice deficient in STAT1 displayed impaired basal NK cytolytic activity in vitro and were unable to reject transplanted tumors in vivo, despite the presence of normal numbers of NK cells. IL-12 enhanced NK-mediated cytolysis, but poly(I:C) did not, and a similar phenotype occurred in mice lacking IFNalpha receptors. Molecules involved in activation and lytic function of NK cells (granzyme A, granzyme B, perforin, DAP10, and DAP12) were expressed at comparable levels in both wild-type and STAT1(-/-) mice, and serine esterase activity necessary for CTL function was normal, showing that the lytic machinery was intact. NK cells with normal cytolytic activity could be derived from STAT1(-/-) bone marrow progenitors in response to IL-15 in vitro, and enhanced NK lytic activity and normal levels of IFN-gamma were produced in response to IL-12 treatment in vivo. Despite these normal responses to cytokines, STAT1(-/-) mice could not reject the NK-sensitive tumor RMA-S, even following IL-12 treatment in vivo. Whereas in vitro NK cytolysis was also reduced in mice lacking both type I and type II IFN receptors, these mice resisted tumor challenge. These results demonstrate that both IFN-alpha and IFN-gamma are required to maintain NK cell function and define a STAT1-dependent but partially IFN-independent pathway required for NK-mediated antitumor activity.
Insights
Signal transducer and activator of transcription 1 (STAT1) is crucial for natural killer (NK) cell antitumor activity. STAT1 deficiency impairs NK cell function, highlighting the importance of STAT1 in maintaining NK cell-mediated tumor rejection.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Research
Background:
- Natural killer (NK) cells are critical immune cells involved in tumor surveillance and rejection.
- Interferon (IFN) signaling pathways, particularly those mediated by Signal transducer and activator of transcription 1 (STAT1), play a significant role in regulating immune cell function.
- The precise role of STAT1 in NK cell-mediated antitumor immunity requires further elucidation.
Purpose of the Study:
- To investigate the function of NK cells in mice with a targeted mutation of the STAT1 gene.
- To determine the impact of STAT1 deficiency on NK cell cytolytic activity and in vivo tumor rejection.
- To elucidate the specific roles of type I and type II interferons in STAT1-dependent NK cell antitumor responses.
Main Methods:
- Analysis of NK cell functions in STAT1-deficient (STAT1(-/-)) mice and wild-type littermates.
- In vitro assessment of NK cell cytolytic activity using various stimuli (IL-12, poly(I:C)).
- In vivo tumor rejection assays using NK-sensitive tumors (RMA-S) in STAT1(-/-) mice, with and without cytokine treatment.
- Examination of the expression of key NK cell activation and lytic molecules (granzyme A, granzyme B, perforin, DAP10, DAP12).
Main Results:
- STAT1(-/-) mice exhibited impaired basal NK cell cytolytic activity in vitro and failed to reject transplanted tumors in vivo.
- NK cell numbers were normal in STAT1(-/-) mice, and the expression of molecules essential for cytolytic function was intact.
- While IL-12 enhanced NK cell-mediated cytolysis, poly(I:C) did not, suggesting a specific defect in IFN signaling.
- NK cells derived from STAT1(-/-) progenitors showed normal responses to IL-15, but STAT1(-/-) mice still could not reject tumors even after IL-12 treatment.
- Mice lacking both type I and type II IFN receptors resisted tumor challenge, despite reduced in vitro NK cytolysis.
Conclusions:
- STAT1 is essential for maintaining NK cell function and mediating antitumor activity.
- Both IFN-alpha (type I) and IFN-gamma (type II) signaling, acting through STAT1, are required for effective NK cell-mediated tumor rejection.
- A STAT1-dependent, but partially IFN-independent pathway contributes to NK cell antitumor immunity.